Wells Fargo’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-130,800
| Closed | -$30.3M | – | 7094 |
|
|
2025
Q3 | $30.3M | Buy |
+130,800
| New | +$26.6M | 0.01% | 1205 |
|
|
2024
Q2 | – | Sell |
-5,600
| Closed | -$1.02M | – | 6861 |
|
|
2024
Q1 | $1.02M | Sell |
5,600
-277,900
| -98% | -$47.9M | ﹤0.01% | 3446 |
|
|
2023
Q4 | $43.9M | Buy |
283,500
+173,800
| +158% | +$25.3M | 0.01% | 792 |
|
|
2023
Q3 | $16.4M | Buy |
109,700
+108,200
| +7,213% | +$15.9M | ﹤0.01% | 1230 |
|
|
2023
Q2 | $202K | Sell |
1,500
-6,600
| -81% | -$968K | ﹤0.01% | 4585 |
|
|
2023
Q1 | $1.29M | Buy |
8,100
+6,600
| +440% | +$1.01M | ﹤0.01% | 3201 |
|
|
2022
Q4 | $242K | Sell |
1,500
-25,100
| -94% | -$3.85M | ﹤0.01% | 4076 |
|
|
2022
Q3 | $3.57M | Buy |
26,600
+1,600
| +6% | +$230K | ﹤0.01% | 2246 |
|
|
2022
Q2 | $3.83M | Buy |
+25,000
| New | +$3.82M | ﹤0.01% | 2290 |
|
|
2022
Q1 | – | Sell |
-237,700
| Closed | -$32.2M | – | 6967 |
|
|
2021
Q4 | $32.2M | Buy |
+237,700
| New | +$28.1M | 0.01% | 1026 |
|
|
2021
Q2 | – | Sell |
-39,400
| Closed | -$4.26M | – | 6839 |
|
|
2021
Q1 | $4.26M | Buy |
+39,400
| New | +$4.21M | ﹤0.01% | 2997 |
|
|
2020
Q4 | – | Sell |
-28,700
| Closed | -$45K | – | 6427 |
|
|
2020
Q3 | $45K | Buy |
+28,700
| New | +$2.7M | ﹤0.01% | 5544 |
|
|
2020
Q2 | – | Sell |
-80,200
| Closed | -$19K | – | 6233 |
|
|
2020
Q1 | $19K | Buy |
80,200
+68,500
| +585% | +$5.83M | ﹤0.01% | 5610 |
|
|
2019
Q4 | $101K | Hold |
11,700
| – | – | ﹤0.01% | 5290 |
|
|
2019
Q3 | $22K | Hold |
11,700
| – | – | ﹤0.01% | 5783 |
|
|
2019
Q2 | $27K | Buy |
+11,700
| New | +$920K | ﹤0.01% | 5722 |
|
|
2018
Q4 | – | Sell |
-46,700
| Closed | -$3K | – | 6352 |
|
|
2018
Q3 | $3K | Buy |
+46,700
| New | +$4.43M | ﹤0.01% | 6169 |
|
|
2017
Q3 | – | Sell |
-25,000
| Closed | -$38K | – | 6286 |
|
|
2017
Q2 | $38K | Buy |
+25,000
| New | +$1.68M | ﹤0.01% | 5463 |
|
|
2017
Q1 | – | Sell |
-160,200
| Closed | -$62K | – | 6281 |
|
|
2016
Q4 | $62K | Buy |
160,200
+100,300
| +167% | +$6.12M | ﹤0.01% | 5317 |
|
|
2016
Q3 | $23K | Buy |
59,900
+2,100
| +4% | +$136K | ﹤0.01% | 5564 |
|
|
2016
Q2 | $30K | Sell |
57,800
-2,200
| -4% | -$134K | ﹤0.01% | 5370 |
|
|
2016
Q1 | $31K | Buy |
+60,000
| New | +$3.34M | ﹤0.01% | 5387 |
|
|
2015
Q4 | – | Sell |
-113,200
| Closed | -$14K | – | 6184 |
|
|
2015
Q3 | $14K | Sell |
113,200
-21,600
| -16% | -$1.41M | ﹤0.01% | 5630 |
|
|
2015
Q2 | $357K | Sell |
134,800
-36,200
| -21% | -$2.36M | ﹤0.01% | 4280 |
|
|
2015
Q1 | $48K | Buy |
+171,000
| New | +$10.3M | ﹤0.01% | 5022 |
|
Other funds holding ABBV
VCM
VPM
Wells Fargo's ABBV Position: Q1 2026 in Review
Wells Fargo reduced its AbbVie (ABBV) stake by 2.6% in Q1 2026, selling an estimated $52.8M and leaving 8,909,597 shares worth $1.94B. The position accounts for 0.37% of the portfolio, ranked #51.
Wells Fargo first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.11B in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Wells Fargo held 8,909,597 shares of AbbVie worth $1.94B as of Q1 2026.
- Wells Fargo sold 238,169 AbbVie shares in Q1 2026, an estimated $52.8M.
- AbbVie made up 0.37% of Wells Fargo's portfolio in Q1 2026, its #51 holding.
- Wells Fargo first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's AbbVie position peaked at $2.11B in Q3 2025.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.